Suven Gets Three Product Patents from Singapore, Australia | CORPORATE ETHOS

Suven Gets Three Product Patents from Singapore, Australia

By: | May 17, 2018

May 17: Hyderabad-based biopharma major Suven Life Sciences Ltd on Thursday said that the grant of two product patents from Australia (2014403999 and 2014404000) and one product patent from Singapore (11201701106R) ) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034.

According to the company, the granted claims of the patents include the class of selective H3 Inverse agonists and 5HT6 compounds respectively and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.